Multiple escalating dose study of BAY 1093884 in adults with hemophilia A or B with or without inhibitors
Phase of Trial: Phase II
Latest Information Update: 05 Dec 2019
Price : $35 *
At a glance
- Drugs BAY 1093884 (Primary)
- Indications Haemophilia A; Haemophilia B
- Focus Adverse reactions
- Sponsors Bayer
- 05 Nov 2019 Status changed from active, no longer recruiting to discontinued.
- 05 Nov 2019 This trial has been completed in Austria, according to European Clinical Trials Database record.
- 23 Oct 2019 This trial has been completed in France, according to European Clinical Trials Database record.